Hangzhou Tigermed Consulting Co., Ltd. Announces Successful AGM and Class Meetings

Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has shared an announcement.

Hangzhou Tigermed Consulting Co., Ltd. successfully held its 2024 Annual General Meeting and the 2025 First A and H Share Class Meetings on May 30, 2025. All proposed resolutions were approved by shareholders through poll voting, confirming the meetings’ compliance with relevant PRC laws and regulations. The meetings were attended by key company officials, and the voting process was overseen by legal advisors and scrutineers to ensure transparency and adherence to legal standards. This outcome reinforces the company’s governance and operational transparency, potentially strengthening its position in the market and assuring stakeholders of its commitment to regulatory compliance.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$38.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates in the consulting industry, focusing on providing clinical trial services and solutions. The company is listed on the Stock Exchange of Hong Kong and is involved in the healthcare sector, offering services that support pharmaceutical and biotech companies in their research and development processes.

Average Trading Volume: 3,548,320

Technical Sentiment Signal: Sell

Current Market Cap: HK$38.84B

Learn more about 3347 stock on TipRanks’ Stock Analysis page.